Brokerages Expect Novavax, Inc. (NASDAQ:NVAX) to Post -$0.85 EPS

Analysts forecast that Novavax, Inc. (NASDAQ:NVAX) will report earnings of ($0.85) per share for the current quarter, Zacks reports. Two analysts have made estimates for Novavax’s earnings. The lowest EPS estimate is ($0.89) and the highest is ($0.81). Novavax reported earnings per share of ($2.40) in the same quarter last year, which indicates a positive year-over-year growth rate of 64.6%. The firm is scheduled to announce its next earnings report on Wednesday, November 6th.

On average, analysts expect that Novavax will report full-year earnings of ($5.81) per share for the current fiscal year, with EPS estimates ranging from ($6.85) to ($4.41). For the next financial year, analysts forecast that the firm will post earnings of ($3.64) per share, with EPS estimates ranging from ($5.47) to ($2.18). Zacks Investment Research’s earnings per share calculations are a mean average based on a survey of sell-side analysts that follow Novavax.

Novavax (NASDAQ:NVAX) last released its quarterly earnings results on Wednesday, August 7th. The biopharmaceutical company reported ($1.69) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($1.61) by ($0.08). The company had revenue of $3.36 million for the quarter, compared to the consensus estimate of $3.53 million. During the same period in the prior year, the firm posted ($2.40) earnings per share.

A number of brokerages have weighed in on NVAX. Chardan Capital reaffirmed a “neutral” rating and set a $7.00 target price on shares of Novavax in a research note on Friday, May 10th. Oppenheimer raised their target price on shares of Novavax from $1.25 to $25.00 in a research note on Monday, May 13th. HC Wainwright raised their target price on shares of Novavax from $10.00 to $17.00 and gave the company a “buy” rating in a research note on Wednesday. Zacks Investment Research raised shares of Novavax from a “hold” rating to a “buy” rating and set a $8.00 target price for the company in a research note on Thursday, May 16th. Finally, ValuEngine raised shares of Novavax from a “sell” rating to a “hold” rating in a research note on Thursday, August 1st. Two research analysts have rated the stock with a sell rating, four have issued a hold rating and six have issued a buy rating to the company’s stock. Novavax has an average rating of “Hold” and an average price target of $40.70.

Several large investors have recently bought and sold shares of NVAX. Millennium Management LLC boosted its holdings in Novavax by 127.8% in the fourth quarter. Millennium Management LLC now owns 2,934,275 shares of the biopharmaceutical company’s stock worth $5,399,000 after purchasing an additional 1,645,934 shares during the last quarter. Edmond DE Rothschild Holding S.A. boosted its holdings in Novavax by 86.7% in the first quarter. Edmond DE Rothschild Holding S.A. now owns 1,537,130 shares of the biopharmaceutical company’s stock worth $847,000 after purchasing an additional 713,752 shares during the last quarter. SG Americas Securities LLC boosted its holdings in Novavax by 3,799.2% in the first quarter. SG Americas Securities LLC now owns 435,107 shares of the biopharmaceutical company’s stock worth $240,000 after purchasing an additional 423,948 shares during the last quarter. Creative Planning boosted its holdings in Novavax by 161.7% in the first quarter. Creative Planning now owns 513,324 shares of the biopharmaceutical company’s stock worth $283,000 after purchasing an additional 317,204 shares during the last quarter. Finally, Metropolitan Life Insurance Co. NY boosted its holdings in Novavax by 296.4% in the fourth quarter. Metropolitan Life Insurance Co. NY now owns 137,288 shares of the biopharmaceutical company’s stock worth $253,000 after purchasing an additional 102,657 shares during the last quarter.

Shares of NASDAQ NVAX traded up $1.80 on Friday, reaching $6.10. 6,025,358 shares of the company’s stock traded hands, compared to its average volume of 770,728. Novavax has a 12 month low of $4.01 and a 12 month high of $51.60. The company has a 50 day moving average of $4.78. The stock has a market cap of $102.87 million, a P/E ratio of -0.61 and a beta of 2.21.

About Novavax

Novavax, Inc, together with its subsidiary, Novavax AB, a late-stage biotechnology company, focuses on the discovery, development, and commercialization of vaccines to prevent serious infectious diseases. The company's lead vaccine candidates include ResVax, a respiratory syncytial virus (RSV) fusion (F) protein recombinant nanoparticle vaccine with aluminum phosphate as an adjuvant that is in Phase III clinical trial to protect infants from RSV disease through maternal immunization; and NanoFlu, which is in Phase II clinical trial for treating seasonal influenza in older adults.

Read More: What is systematic risk?

Get a free copy of the Zacks research report on Novavax (NVAX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Novavax (NASDAQ:NVAX)

Receive News & Ratings for Novavax Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novavax and related companies with MarketBeat.com's FREE daily email newsletter.